Novartis AG SG&A Expenses 2012-2026 | NVS

Novartis AG sg&a expenses for the twelve months ending March 31, 2026 were $13.330B, a 4.27% increase year-over-year.

  • Novartis AG annual sg&a expenses for 2025 were $13.248B, a 5.43% increase from 2024.
  • Novartis AG annual sg&a expenses for 2024 were $12.566B, a 0.39% increase from 2023.
  • Novartis AG annual sg&a expenses for 2023 were $12.517B, a 2.66% increase from 2022.

Novartis AG SG&A Expenses 2012-2026 | NVS

  • Novartis AG annual sg&a expenses for 2025 were $13.248B, a 5.43% increase from 2024.
  • Novartis AG annual sg&a expenses for 2024 were $12.566B, a 0.39% increase from 2023.
  • Novartis AG annual sg&a expenses for 2023 were $12.517B, a 2.66% increase from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B